SCHEMBL23744768

SCHEMBL23744768

C[C@@H]1CN(c2cnc(Cl)cn2)C[C@H](C)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
HDAC1 Q13547 1/20 0.39
PTPN11 Q06124 4/20 0.39
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
SMO Q99835 1/20 0.36
CNR2 P34972 1/20 0.36
CDK4 P11802 1/20 0.36
PANK3 Q9H999 1/20 0.36
TNKS O95271 1/20 0.35
PARP1 P09874 1/20 0.35
PARP15 Q460N3 1/20 0.35
PARP14 Q460N5 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
HTT P42858 1/20 0.35
OGA O60502 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345800 1.00 CHRNB4 (0.39) CHRNB4CHRNA3HDAC1PTPN11CHRNB2
SCHEMBL23744094 1.00 CHRNB4 (0.39) CHRNB4CHRNA3HDAC1PTPN11CHRNB2
SCHEMBL82255 0.82 HDAC1 (0.40) HDAC1PTPN11CHRNB2CHRNA4SMO
SCHEMBL20071399 0.82 CHRNB4 (0.57) CHRNB4CHRNA3CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL23607806 0.81 CHRNB4 (0.56) CHRNB4CHRNA3CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL29566662 0.81 CHRNB4 (0.56) CHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL22795905 0.79 CNR2 (0.39) CHRNB4CHRNA3CHRNB2CHRNA4CHRM2
SCHEMBL30345463 0.79 JAK2 (0.40) HDAC1CHRM4CDK4PANK3PARP1
SCHEMBL26429853 0.79 JAK2 (0.40) HDAC1CHRM4CDK4PANK3PARP1
SCHEMBL22795652 0.78 CHRNB4 (0.38) CHRNB4CHRNA3CHRNB2CHRNA4CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 CHRNB4 11/4885CHRNA3 12/4885HDAC1 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.